Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1981 3
1983 2
1984 2
1985 3
1986 1
1987 13
1988 10
1989 6
1990 3
1991 6
1992 6
1993 4
1994 6
1995 8
1996 3
1997 5
1998 2
1999 9
2000 8
2001 5
2002 10
2003 10
2004 4
2005 14
2006 7
2007 9
2008 7
2009 16
2010 11
2011 4
2012 19
2013 12
2014 15
2015 27
2016 18
2017 24
2018 19
2019 22
2020 27
2021 29
2022 16
2023 21
2024 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

417 results

Results by year

Filters applied: . Clear all
Page 1
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Jayne DRW, et al. N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386. N Engl J Med. 2021. PMID: 33596356 Clinical Trial.
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO, van Leew B, Bertsias G, Jayne D, Boumpas DT. Fanouriakis A, et al. Among authors: praga m. Ann Rheum Dis. 2020 Jun;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924. Epub 2020 Mar 27. Ann Rheum Dis. 2020. PMID: 32220834
Acute interstitial nephritis.
Praga M, González E. Praga M, et al. Kidney Int. 2010 Jun;77(11):956-61. doi: 10.1038/ki.2010.89. Epub 2010 Mar 24. Kidney Int. 2010. PMID: 20336051 Free article. Review.
Glomerular diseases in pregnancy: pragmatic recommendations for clinical management.
Fakhouri F, Schwotzer N, Cabiddu G, Barratt J, Legardeur H, Garovic V, Orozco-Guillen A, Wetzels J, Daugas E, Moroni G, Noris M, Audard V, Praga M, Llurba E, Wuerzner G, Attini R, Desseauve D, Zakharova E, Luders C, Wiles K, Leone F, Jesudason S, Costedoat-Chalumeau N, Kattah A, Soto-Abraham V, Karras A, Prakash J, Lightstone L, Ronco P, Ponticelli C, Appel G, Remuzzi G, Tsatsaris V, Piccoli GB. Fakhouri F, et al. Among authors: praga m. Kidney Int. 2023 Feb;103(2):264-281. doi: 10.1016/j.kint.2022.10.029. Epub 2022 Dec 5. Kidney Int. 2023. PMID: 36481180 Review.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Targeting complement in IgA nephropathy.
Caravaca-Fontán F, Gutiérrez E, Sevillano ÁM, Praga M. Caravaca-Fontán F, et al. Among authors: praga m. Clin Kidney J. 2023 Dec 4;16(Suppl 2):ii28-ii39. doi: 10.1093/ckj/sfad198. eCollection 2023 Dec. Clin Kidney J. 2023. PMID: 38053977 Free PMC article. Review.
Update on C3 Glomerulopathy: A Complement-Mediated Disease.
Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Caravaca-Fontán F, et al. Among authors: praga m. Nephron. 2020;144(6):272-280. doi: 10.1159/000507254. Epub 2020 May 5. Nephron. 2020. PMID: 32369815 Free article. Review.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Among authors: praga m. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.
Inker LA, Heerspink HJL, Tighiouart H, Chaudhari J, Miao S, Diva U, Mercer A, Appel GB, Donadio JV, Floege J, Li PKT, Maes BD, Locatelli F, Praga M, Schena FP, Levey AS, Greene T. Inker LA, et al. Among authors: praga m. Am J Kidney Dis. 2021 Sep;78(3):340-349.e1. doi: 10.1053/j.ajkd.2021.03.007. Epub 2021 Mar 26. Am J Kidney Dis. 2021. PMID: 33775708 Free PMC article. Review.
417 results